Therapeutic oligonucleotides: The road not taken

Cy A. Stein, Sanjay Goel

Research output: Contribution to journalArticle

10 Scopus citations


Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

Original languageEnglish (US)
Pages (from-to)6369-6372
Number of pages4
JournalClinical Cancer Research
Issue number20
Publication statusPublished - Oct 15 2011


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this